Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).
Japanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in 'off-the-shelf' cell therapies for solid tumours and blood cancers.
The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo
NICE has decided not to recommend Seagen's orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, saying it isn't a cost-effective use of NHS resources.<
Expectations for Novartis' canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objecti